Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics.
Calabretta E, Guidetti A, Ricci F, Di Trani M, Monfrini C, Magagnoli M, Bramanti S, Maspero D, Morello L, Merli M, Di Rocco A, Graudenzi A, Derenzini E, Antoniotti M, Rossi D, Corradini P, Santoro A, Carlo-Stella C. Calabretta E, et al. Among authors: guidetti a. Br J Haematol. 2022 Jul;198(1):82-92. doi: 10.1111/bjh.18183. Epub 2022 Apr 25. Br J Haematol. 2022. PMID: 35468225 Free PMC article.
Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with defibrotide and recombinant human granulocyte colony-stimulating factor.
Carlo-Stella C, Di Nicola M, Longoni P, Milani R, Milanesi M, Guidetti A, Haanstra K, Jonker M, Cleris L, Magni M, Formelli F, Gianni AM. Carlo-Stella C, et al. Among authors: guidetti a. Exp Hematol. 2004 Jan;32(1):68-75. doi: 10.1016/j.exphem.2003.09.022. Exp Hematol. 2004. PMID: 14725903 Free article.
Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers.
Carlo-Stella C, Di Nicola M, Milani R, Guidetti A, Magni M, Milanesi M, Longoni P, Matteucci P, Formelli F, Ravagnani F, Corradini P, Gianni AM. Carlo-Stella C, et al. Among authors: guidetti a. Blood. 2004 May 1;103(9):3287-95. doi: 10.1182/blood-2003-07-2428. Epub 2004 Jan 15. Blood. 2004. PMID: 14726397 Free article. Clinical Trial.
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
Di Nicola M, Carlo-Stella C, Mortarini R, Baldassari P, Guidetti A, Gallino GF, Del Vecchio M, Ravagnani F, Magni M, Chaplin P, Cascinelli N, Parmiani G, Gianni AM, Anichini A. Di Nicola M, et al. Among authors: guidetti a. Clin Cancer Res. 2004 Aug 15;10(16):5381-90. doi: 10.1158/1078-0432.CCR-04-0602. Clin Cancer Res. 2004. PMID: 15328176 Clinical Trial.
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.
Devizzi L, Guidetti A, Tarella C, Magni M, Matteucci P, Seregni E, Chiesa C, Bombardieri E, Di Nicola M, Carlo-Stella C, Gianni AM. Devizzi L, et al. Among authors: guidetti a. J Clin Oncol. 2008 Nov 10;26(32):5175-82. doi: 10.1200/JCO.2008.16.8294. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854569 Clinical Trial.
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).
Chiesa C, Botta F, Coliva A, Maccauro M, Devizzi L, Guidetti A, Carlo-Stella C, Seregni E, Gianni MA, Bombardieri E. Chiesa C, et al. Among authors: guidetti a. Eur J Nucl Med Mol Imaging. 2009 Nov;36(11):1745-57. doi: 10.1007/s00259-009-1141-x. Epub 2009 May 20. Eur J Nucl Med Mol Imaging. 2009. PMID: 19455328 Clinical Trial.
90 results